Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)

Détails bibliographiques
Auteurs principaux: Catovsky, D, Richards, S, Dearden, C, Matutes, E, Dyer, M, Hillmen, P
Format: Conference item
Publié: 2006

Documents similaires